Targeting lung inflammation: Novel therapies for the treatment of COPD

Current Respiratory Medicine Reviews

Volumn 4, Issue 1, 2008, Pages 57-68

  Yao, Hongwei ^a   de Boer, Willem I ^b   Rahman, Irfan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antagonists; Cigarette smoke; Cytokines; MAP kinase; MMPs; NF B

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCL1 ANTAGONIST; CILOMILAST; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HISTONE DEACETYLASE INHIBITOR; I KAPPA B KINASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 8 RECEPTOR ANTAGONIST; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ONO 6818; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALMETEROL; SB 681323; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TARGETING; EVIDENCE BASED MEDICINE; GLAUCOMA; HUMAN; LUNG EMPHYSEMA; LUNG FUNCTION TEST; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SKIN BRUISING; SMOKING CESSATION;

EID: 39449132833     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339808783497873     Document Type: Review

References (138)

1. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532.
2. Lindberg A, Bjerg-Backlund A, Ronmark E, et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2006; 100: 264-272.
3. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.
4. Pauwels RA, and Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620.
5. Hoogendoom M, Feenstra TL, and Rutten-van Molken MP. [Projections of future resource use and the costs of asthma and COPD in the Netherlandsl. Ned Tijdschr Geneeskd 2006; 150: 1243-1250.
6. Hynninen KM, Breitve MH, Wiborg AB, et al. Psychological characteristics of patients with chronic obstructive pulmonary disease: a review. J Psychosom Res 2005; 59: 429-443.
7. Jones PW. Health status: what does it mean for payers and patients? Proc Am Thorac Soc 2006, 3: 222-226.
8. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
9. Snider GL. Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu Rev Med 1989; 40: 411-429.
10. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939.
11. Sampsonas F, Karkoulias K, Kaparianos A, et al. Genetics of chronic obstructive pulmonary disease, beyond al-antitrypsin deficiency. Curr Med Chem 2006; 13: 2857-2873.
12. Voelkel NF, and Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46: 28s-32s.
13. JeffieTy PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000; 117: 251S-260S.
14. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110.
15. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
16. Molfino NA, and Jeffery PK. Chronic obstructive pulmonary disease: Histopathology, inflammation and potential therapies. Pulm Pharmacol Ther 2007; 20: 462-472.
17. Rutgers SP, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109-115.
18. Barnes NC, Qiu YS, Pavord JD, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
19. Hattotuwa KL, Gizycki MJ, Ansari TW et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-1596.
20. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
21. Rabe KF. Treating COPD-the TORCH trial, P values, and the Dodo. N Engl J Med 2007; 356: 851-854.
22. Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corficosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Am Fam Med 2006; 4: 253-262.
23. Barnes PJ, and Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084-1106.
24. Gan WQ, Ma SF, and Sin DD. Effect of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5: 2.
25. McEvoy CE, and Niewoehner DE. Adverse. effect of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732-743.
26. Franciosi LG, Page CP, Celli BR, et al. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006; 7: 74.
27. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 3-1: in press.
28. Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of COPD - 2006 Update. Am J Respir Crit Care Med 2007; 176: 532-555.
29. Barber R, Baillie GS, Bergmann R, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mot Physiol 2004; 287: L332-343.
30. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-571.
31. Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006; 129: 56-66.
32. Grootendorst DC, Gauw SA, and Sterk PJ. Treatment with PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Proc Am Thoracic Soc 2005; 2: A543.
33. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976-982.
34. Houslay MD, and Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk desensitization and compartmentalization. Biochem J 2003; 370: 1-18.
35. Lamontagne S, Meadows E, Luk P, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001; 920: 84-96.
36. Robichaud A, Stamatiou PB, An SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045-1052.
37. Jin SL, and Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002; 99: 7628-7633.
38. Johnson GL, and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
39. Meja M Seldon PM, Nasuhara Y, et al. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. Br J Pharmacol 2000; 131: 1143-1153.
40. Kumar S, Boehm J, and Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-726.
41. Lee JC, Kassis S, Kumar S, et al. p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 1999; 82: 389-397.
42. Haeryfar SM, and Hoskin DW. Selective pharmacological inhibitors reveal differences between Thy-1- and T cell receptor-mediated signal transduction in mouse T lymphocytes. Int Immunopharmacol 2001; 1: 689-698.
43. Zhang J, Salojin KV, Gao JX, et al. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation. in primary murine T cells. J Immunol 1999; 162: 3819-3829.
44. Rincon M, Enslen H, Raingeaud J, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 1998; 17: 2817-2829.
45. Hitti E, Iakovleva T, Brook M, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adinine/uridine-rich element. Mol Cell Biol 2006; 26: 2399-2407.
46. Briata P, Forcales SV, Ponassi M, et al. p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic; transcripts. Mol Cell 2005; 20: 891-903.
47. Dean JL, Sully G, Clark AR, et al. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004; 16: 1113-1121.
48. Parasrampuria DA, de Boer P, Desai-Krieger D, et al. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol 2003; 43: 406-413.
49. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L895-902.
50. Haddad EB, Birrell M, McCluskie K, et al. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 2001; 132: 1715-1724.
51. Matsuoka H, Arai T, Mori M, et al. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002; 283: L103-112.
52. Underwood DC, Osborn RR, Kotzer CJ, et al. SB 239063, a potent p38 MAP kiuase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000; 293: 281-288.
53. Ghosh S, May MJ, and Kopp EB. NF-kappa B and Re1 proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immumol 1998; 16: 225-260.
54. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
55. Delhase M, Li N, and Karin M. Kinase regulation in inflammatory response. Nature 2000; 406: 367-368.
56. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003; 13: 2419-2422.
57. Jazrawi E, Cosio BG, Barnes PJ, et al. Inhibition of IKK2 and JNK differentially regulates GM-CSF and IL-8 release in epithelial cells and alveolar macrophages. Am J Respir Crit Care Med 2003; 167: A798.
58. Nasuhara Y, Adcock IM, Catley M, et al. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. J Biol Chem 1999; 274: 19965-19972.
59. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
60. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activition of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-286.
61. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
62. Holmes-McNary M, and Baldwin AS, Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000; 60: 3477-3483.
63. Tsai SH, Lin-Shiau SY, and Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 1999; 126: 673-680.
64. Ezeamuzie CI, Sukumaran J, and Philips E. Effect of wortmannin on human eosihophil responses in vitro and on bronchial inflammation and airway hyperresponsiveness in Guinea pigs in vivo. Am J Respir Crit Care Med 2001; 164: 1633-1639.
65. Duan W, Aguinaldo Datiles AM, Leung BP, et al. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 2005; 5: 495-502.
66. Lee KS, Kim SR, Park SJ, et al. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol Pharmacol 2006; 60: 1829-1839.
67. Kwak YG, Song CH, Yi HK, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 2003; 111: 1083-1092.
68. Thomas MJ, Smith A, Head DH, et al. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol 2005; 35: 1283-1291.
69. Barnes PJ, Shapiro SD, and Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
70. Ko HM, Kang JH, Choi JH, et al. Platelet-activating factor induces matrix metalloproteinase-9 expression through Ca(2+)- or PI3K-dependent signaling pathway in a human vascular endothelial cell line. FEBS Lett 2005; 579: 6451-6458.
71. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976.
72. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203: 7-13.
73. Ito K, Caramori G, and Adcock IM. Therapeutic potential of P13K inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 2007; 321: 1-8.
74. De Boer WI, Alagappan VK, and Sharma HS. Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. Cell Biochem Biophys 2007; 47: 131-148.
75. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006; 7: 675-681.
76. de Boer WI. Perspectives for cytokine antagonist therapy in COPD. Drug Discov Today 2005; 10: 93-106.
77. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
78. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218-1224.
79. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1179-1184.
80. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-934.
81. van der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 465-469.
82. Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin Investig Drugs 2006; 15: 181-184.
83. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174: 753-762.
84. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthm. N Engl J Med 2006; 354: 697-708.
85. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018.
86. Bruce C, and Thomas PS. The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 2005; 205: 126-132.
87. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.
88. Yang XD, Corvalan JR, Wang P, et al. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66: 401-410.
89. Hill AT, Bayley D, and Stockley RA. The interrelationship of sputum inflammatory markets in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893-898.
90. Beeh KM, Kommann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-1247.
91. Nicholson GC, Tennant RC, Carpenter DC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther 2007; 20: 52-59.
92. Liao L, Ning Q, Li Y, et al. CXCR2 blockade reduces radical formation in hyperoxia-exposed newborn rat lung. Pediatr Res 2006; 60: 299-303.
93. Auten RL, Richardson RM, White JR, et al. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther 2001; 299:90-95.
94. De Boer WI. Cytokines and therapy in COPD: a promising combination? Chest 2002; 121: 209S-218S.
95. Baxter A, Cooper A, Kinchin E, et al. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett 2006; 16: 960-963.
96. Dwyer MP, Yu Y, Chao J, et al. Discovery of 2-Hydroxy-N,N-dimethyl-3-{2- (R)-1-(5-[[methylfuran2-yl)propyl]amino]- 3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist. J Med Chem 2006; 49: 7603-7606.
97. Ho KK, Auld DS, Bohnstedt AC, et al. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg Med Chem Lett 2006; 16: 2724-2728.
98. Capelli A, Di Stefano A, Gnemmi I, et al. Incrrased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999; 14: 160-165.
99. de Boer WI, Sont K van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190: 619-626.
100. Traves SL, Culpitt SV, Russell RE, et al. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002; 57: 590-595.
101. Ko FW, Lau CY, Leung TF, et al. Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir Med 2006; 100: 630-638.
102. Haringman JJ, Gerlag DM, Smeets TJ, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2387-2392.
103. Butora G, Morriello GJ, Kothandaraman S, et al. 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties. Bioorg Med Chem Lett 2006; 16: 4715-4722.
104. Pasternak A, Marino D, Vicario PP, et al. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists. J Med Chem 2006; 49: 4801-4804.
105. Brodmerkel CM, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005; 175: 5370-5378.
106. Ferry C, Lonchampt K Pennel L, et al. Activation of MMP-9 by neutpophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997; 402: 111-115.
107. Okada Y, Watanabe S, Nakanishi I, et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 1988; 229: 157-160.
108. Chughtai B, and OlUordan TG. Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med 2004; 17: 289-298.
109. Shapiro SD, Goldstein NM, Houghton AM, et al. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 2003; 163: 2329-2335.
110. MacIvor DM, Shapiro SD, Pham CT, et al. Normal neutrophil function in cathepsin G-deficient mice. Blood 1999; 94: 4282-4293.
111. Loike JD, Sodeik B, Cao L, et al., CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. Proc Natl Acad Sci U S A 1991;88: 1044-1048.
112. Pemberton PA, Kobayashi D, Wilk BJ, et al. Inhaled recombinant-alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Copd 2006; 3: 101-108.
113. Churg A, Wang RD, Xie C, et al. alpha-l-Antitrysin ameliorates cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2003; 168: 199-207.
114. Wright JL, Farmer SG, and Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med 2002; 166: 954-960.
115. Edwards PD, Andisik DW, Bryant CA, et al. Discovery and biological activity of orally active peptidyl trifluoromethyl ketone inhibitors of humak neutrophil elastase. J Med Chem 1997; 40: 1876-1885.
116. Vincent SH, Painter SK, Luffer-Atlas D, et al. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys. Drug Metab Dispos 1997; 25: 932-939.
117. Finlay GA, Russell KJ, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patient. Thorax 1997; 52: 502-506.
118. Ohnishi K, Takagi M, Kurokawa Y, et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998; 78: 1077-1087.
119. Cataldo D, Munaut C, Noel A, et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123: 259-267.
120. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950.
121. Finlay GA, O'Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156: 240-247.
122. Bracke K, Cataldo D, Maes T, et al. Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. Int Arch Allergy Immunol 2005; 138: 169-179.
123. Demedts IK, Morel-Montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 2006; 61: 196-201.
124. Hautamaki RD, Kobayashi DY, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997; 277: 2002-2004.
125. Nenan S, Lagente V, Planquois JM, et al. Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol 2007; 559: 75-81.
126. Belvisi MG, and Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 2003; 52: 95-100.
127. Roth SY, Denu JM, and Allis CD. Historic acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
128. Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87: 953-959.
129. Ito K, Lim S, Caramori G, et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001; 15: 1110-1112.
130. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mot Biol 2004; 31: 633-642.
131. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004; 18: 1897-1899.
132. Rahman I, Gilmour PS, Jimenez LA, et al. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002; 234-235: 239-248.
133. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426.
134. Rahman I, Marwick J, and Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pTo-inflammatory gene expression. Biochem Pharmacol 2004; 68: 1255-1267.
135. Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit
136. Care Med 2003; 167: 24-31.
137. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
138. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999; 14: 309-314.